Arbutus Biopharma Corp — Form SCHEDULE 13D/A
Filed October 5, 2026 · analyzed by the Ownership Agent
SCHEDULE 13D/A
— Neutral
significance 12/100
What the filing says
This is an amended Schedule 13D filing that lists the covered persons (board members) of Roivant Sciences Ltd., a company in which Arbutus holds an interest. The filing names 8 directors including Matthew Gline (CEO), Melissa Epperly (CFO), and board members from QVT Financial LP, Patient Square Capital, and other healthcare entities. No specific share counts, ownership percentages, dollar amounts, or transaction details are provided in this disclosure excerpt—it is a standard governance filing updating board composition.
Why this rating
Routine governance disclosure of board members; no material transaction, ownership change, or financial impact disclosed. Administrative update only.
See more from October 5, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.